Reckitt Opens OTC Manufacturing Facility

Reckitt Benckiser Group Plc has acquired a pharmaceutical site in Wilson, NC, that will expand its US manufacturing footprint and allow it to produce Mucinex tablets and liquids to meet increased consumer demand for cold and flu symptom relief in the US.

Reckitt is investing $200 million to establish a state-of-the-art Mucinex manufacturing facility in North Carolina. The investment will ensure a more resilient supply chain in its largest market.

Located in the vicinity of the “Research Triangle,” among the most important life science hubs in the US, the Wilson factory, roughly 310,000 square feet, will become Reckitt’s biggest over-the-counter (OTC) manufacturing facility in the US and is expected to create nearly 300 jobs. The facility will manufacture a wide range of tablets.

“Mucinex is our No. 1 over-the-counter product in the US and the No. 1 global cough and decongestant medicine so, with the rise in demand for cold and flu relief, we are taking action to expand access to our products and build a more resilient supply chain,” said Harald Emberger, chief supply officer, Reckitt. “The Wilson facility will greatly increase our Mucinex production capacity, localize more manufacturing and enable us to better serve our customers and consumers.”

In the future, the facility also will have capabilities to support additional products including Move Free and Biofreeze. In addition to creating hundreds of new factory jobs, the facility will also support local jobs in construction, engineering and transportation to help distribute Reckitt products across the country.